Bill 218: Supporting Ontario’s Recovery Act, 2020

by Valerie Wise October 23, 2020 3 min read

On October 20, 2020, the Ontario government introduced legislation to provide protection from liability for workers, volunteers and organizations who make “good faith efforts” to comply with federal, provincial or municipal law and public health guidance relating to COVID-19.   

Proposed Act Relates to Claims for Infection or Exposure to COVID-19

The proposed Act would bar claims arising from infection or exposure to COVID-19 on or after March 17, 2020, as long as the individual or organization made “a good faith effort” to act in accordance with the law and public health guidance relating to COVID-19 and was not grossly negligent.

In announcing the Bill, Attorney General Doug Downey said that the legislation was intended to provide protection for men and women who are making essential contributions to our communities during the pandemic (e.g., healthcare workers and institutions; workers in grocery stores; and volunteers at local food banks).  British Columbia and Nova Scotia have similar legislation in place.

“Good faith effort” is defined in the proposed Act as “including” an “honest effort, whether or not that effort is reasonable”.  The proposed Act would still permit legal action against those acting in bad faith or with gross negligence.

The Scope of “Public Health Guidance” is Murky and Seemingly Broad

The legal requirements with which individuals and organizations must comply is broadly defined but at least can be determined:  “a statute or any regulation, order, by-law or other instrument made under a statute”.

The scope of the “public health guidance” with which individuals and organizations must comply is a bit murkier because while it includes some obvious sources of directives, it also includes “employees” of boards of health, government agencies, municipalities, or regulatory bodies; and the “public health guidance” can be communicated in  any way (“regardless of the form or manner of their communication”).

Significantly, the proposed Act also states that the protection applies “regardless of any conflict or inconsistency in the public health guidance or laws applicable to the person” – which is important given the uncertainty and conflict in messaging at least early in the pandemic.

Retroactive Effect

The proposed Act would have retroactive effect and any proceeding commenced before the Act comes into force would be deemed to have been dismissed, without costs, on the day the Act comes into force. The proposed Act also states that no one is entitled to any compensation for the extinguishment or termination of rights under the Act.

Exceptions

The proposed Act would not apply to businesses or aspects of businesses that were required by law to be closed at the material time.  There are also exceptions for certain claims by employees.

Conclusion

Bill 218 is through First Reading and was debated (Second Reading) on October 22, 2020.  If passed, it will have a significant impact not only on litigation in the future, but on some claims that have already been issued.  It is a welcome relief for frontline workers and organizations navigating the challenges of COVID-19 in the midst of ever-changing and sometimes conflicting directives and expectations from government and public health.

Disclaimer:  Our blog is not legal advice and is never a substitute for legal advice specific to your situation.  At the time of this posting, Bill 218 is draft legislation and is not in force.



Also in Blog

Cases to Watch: Marchi v. Nelson

by Mina Karabit September 22, 2020 3 min read

In August 2020, the Supreme Court heard and granted leave to appeal in Marchi v. Nelson, a case from the British Columbia Court of Appeal. The decision is one to watch as it will likely result in a renewed discussion of the distinction of policy versus operational decisions and their impacts on liability in tort law. The discussion will likely impact many of the anticipated post-COVID-19 lawsuits against public and government institutions.
Judicial Review: New Time Limits and a Helpful Primer

by Mina Karabit September 17, 2020 4 min read

In December 2019, Ontario’s Attorney General introduced Bill 161, the Smarter and Stronger Justice Act (the “Act”), which became law on July 8, 2020. The Act hopes to simplify a complex and outdated justice system by bringing changes to how legal aid services are delivered, how class actions are handled, and how court processes are administered.

Of note, the Act has amended the Judicial Review Procedures Act (JRPA) to establish new rules as to when an application for judicial review may be brought.

Any decisions made on or after July 8, 2020 are now subject to a 30-day limit for bringing an application for judicial review unless another Act provides otherwise. Courts, however, retain powers to extend the time for making an application for judicial review if satisfied that there are apparent grounds for relief and that no prejudice or hardship will be incurred by the delay. Before these amendments, the JRPA did not set out any time limits for bringing an application, but courts had powers to extend the time to bring an application if another Act prescribed the limit.

Recent Exemptions for Psychedelic Therapy in Canada

by Mina Karabit August 14, 2020 3 min read

In early August 2020, the Federal Minister of Health granted an exemption under the Controlled Drugs and Substances Act (CDSA) to four terminally ill Canadians to use psilocybin in their end of life care.

Psilocybin is one of the active ingredients/chemicals in “magic mushrooms,” the other is psilocin. Both psilocybin and psilocin are controlled substances under Schedule III of the CDSA. The sale, possession, production, etc. are prohibited unless authorized for clinical trial or research purposes under Part J of the Food and Drug Regulations. Both have been illegal in Canada since 1974. According to Health Canada, there are no approved therapeutic products containing psilocybin in Canada. However, the purified active ingredient, i.e. psilocybin, is being studied in supervised clinical settings for its potential to treat various conditions such as anxiety and depression.